BioValley Business Angels Club (BioBAC)
BioBAC präsentiert seinen Mitglieder attraktive Beteiligungsmöglichkeiten im Bereich Life Sciences Start-ups, um Risikokapital und andere Ressourcen zur Verfügung zu stellen.
BioBAC matches its members with interesting life sciences start-ups to ensure risk capital and other resources needed. See "About us
" for details.
"Entrepreneurs during the Pandemic"
with Ulf Grawunder, Martin Gertsch and Kobi Benenson plus two Start-Up Show Cases building up during the pandemic followed by Networking Apéro
Thursday, 26 August 2021, 5.15 p.m.
Restaurant Safran Zunft Basel,
Gerbergasse 11, 4051 Basel
17:15 Entrepreneurs during the Pandemic,
Ulf Grawunder, Martin Gertsch, Kobi Benenson
17:50 Aukera: Start-Up Show Case 1
Dr. Stefan Imseng
18:10 Asterivir: Start-Up Show Case 2
Oscar Buset, COE
18:30 Networking Apéro
For organizational purposes please pre-register for this event (including whether you have been vaccinated or otherwise have a COVID certificate) until 19 August 2021 either via the following link:
or by e-mail <email@example.com> or Fax: 058 211 33 10. Thank you.
Depending on the COVID development we may restrict access to persons with a valid COVID-certificate or limit access to 100 persons. You will not get a confirmation - if you do not receive a negative answer from us, your registration is accepted. There is no participation fee. The presentations will be held in English.
Ulf Grawunder is the scientific founder of NBE-Therapeutics and serves as Chief Executive Officer (CEO) and Board member at NBE-Therapeutics, which, since January 2021, is a wholly owned subsidiary of Boehringer Ingelheim. Ulf Grawunder is inventor of the proprietary ADC engineering technologies at NBE-Therapeutics which are the basis of NBE’s next-generation antibody drug conjugates (ADCs) for cancer therapy.
Martin Gertsch is Chairman of ARTIDIS, in Basel and a Board Member of the University Center of Dentistry, Basel (UZB).
Kobi Benenson is a Professor at the D-BSSE department of ETH Zürich in Basel, and a co-founder of the start-up Pattern BioSciences. The company is focused on developing the next generation of advanced gene therapies using biomolecular computing and synthetic biology approaches.
Aukera discovers and develops new pharmaceutical drugs with applications in mTOR-related disorders. The lead program selectively targets mTOR complex 1 with a novel mode of action. Aukera is incubated at the Biozentrum of the University of Basel and is supported by Prof. Timm Maier and Prof. Michael N. Hall.
Asterivir is a spin-out from the EPFL lab of Prof. Francesco Stellacci, licensing patents on broad-spectrum antivirals invented well before the emergence of SARS-CoV-2. Molecules employ a novel mechanism of action that renders circulating virions uninfective, showing superiority over oseltamivir (Tamiflu) in head-to-head comparisons in mice. Besides H1N1, the technology has also proven to be effective in-vivo against RSV, HSV-2 and most recently SARS-CoV-2.
Webinar on Monday 7 June 2021, 17:00 pm - 18:15 pm
mRNA – an unexpected breakthrough in biomedical R&D
The pandemic has accelerated the breakthrough of mRNA technology and allowed to develop in record time, allowed the development of a completely new class of vaccines, which are currently rolled out every day in the thousands to protect the global population from the dangerous new virus.
Our panelist discuss:
How three decades of tireless basic research laid the foundation for a completely new class of vaccines ready in time to address the pandemic urgency.
Which key scientific questions concerning mRNA drive basic research today?
How the mRNA vaccination works to activate the immune system effectively and selectively.
What we can learn from the rapid development and regulatory process to get a new product on the market within 1 year from design to approval
How the agility of the technology could be used to quickly address further pandemic needs (e.g. SARS CoV2 mutants) and other infectious diseases (e.g. influenza)
What is the potential of mRNA technology byond the treatment of viral diseases (e.g., cancer, autoimmune diseases and even allergies.
What impact this technology could have on the life-sciences start-up scene.
Anne Spang is Professor at the Biozentrum in Basel since 2005 and heads a Research Group on principles of intracellular organization, in particular how RNA localization, translation and metabolism contribute to cellular asymmetry and defense against stress. From 1999 – 2006 she was a group leader at the Friedrich Miescher Laboratory of the Max Planck Society in Tübingen and before that researcher at HHMI, University of Califor-nia at Berkeley. She was graduate student at the Max Planck Institute for Biochemis-try in Martinsried and studied Biochemistry at the University Pierre et Marie Curie in Paris, and Chemical Engineering at the University of Applied Science Darmstadt.
Friedrich Metzger Prof. Dr. Friedrich Metzger, a scientist and co-founder of Versameb, a Basel based privately held company focusing on discovering and developing innovative mRNA-based drugs for modulation of protein expression and cellular targeting. He has an over 18 years’ experience in R&D both in pharma and biotech. Previously, Friedrich was Head of Discovery, Rare Diseases at Roche, Basel, where he was responsible for a portfolio of highly innovative development programs. He led preclinical activities for Evrysdi™ (risdiplam), a groundbreaking oral therapy for spinal muscular atrophy which was very recently approved. Friedrich is also Professor in Neurobiology at the University of Freiburg i.B.and holds a PhD degree in pharmacology from the University of Tübingen.
Andreas Wallnoefer is General Partner at BioMedPartners, Basel, Switzerland and board member of several European biotech companies. He is a senior executive leader with more than 20 years of experience in the pharmaceutical industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Leadership and Portfolio Committee. He was Head of Roche Clinical Research & Exploratory Development and later of the Pharma Cardiovascular & Metabolism Disease Area. He left Roche in 2015 after the company strategically decided to exit these research areas. He subsequently has been involved in the foundation and development of several successful start-ups. He holds a PhD in Pharmacology from the University of Basel and was trained as a fellow in Clinical Pharmacology at the University of Leiden, Netherlands. He also holds an Executive MBA from IMD Lausanne.
Trudi Haemmerli, Board BioValley Basel & Matthias Staehelin, President BioValley Basel
Before the webinar you can submit your questions to the experts by e-mail to firstname.lastname@example.org.
This webinar will be held in English.
Please register for the webinar using the button below.
BioValley Basel Association
BioValley Business Angels Club
c/o JFG Life Sciences Stiftung
The publisher cannot be held liable for the correctness, completeness and topicality of any contents or presentations in this News Alert. Copyright © 2021 VISCHER AG; Zurich/Basel/Geneva. All rights reserved.
Under below Link you find our information on Data Protection:
/tmp/sites/35209/Data Protection BioBac.pdf
Latest Events of BioValley:
/tmp/sites/35209/Invitation 76 - 19_08_20 (1).pdf
77th BioValley Business Angels Club BioBAC Meeting
Wednesday, December 2nd, 2020, 12.30 p.m.
Virtual Meeting using Zoom
12.30 h Opening remarks, Peter Burckhardt, President BioBAC
12.35 h SunRegen Healthcare AG, Allschwil, Mark Freedman, CEO
12.55 h Oncobit AG, Zürich, Claudia Scheckel, CEO
13.15 h Inmodi, Lausanne, Olga Motovilova, Co-founder & CEO
13.35 h Regenosca SA, Lausanne, Dr. Mattias Larsson, CEO, Co-founder
13.55 h Closing remarks, end